Myria Biosciences AG

Myria Biosciences AG is a Basel-based drug discovery company that combines synthetic biology and artificial intelligence to engineer complex, nature-inspired therapeutic molecules. Its core technology, the Genetically Engineered Modular Molecular Scaffolds (GEMMS) platform, uses AI-guided biosynthesis to reprogram the biosynthetic machinery of cells. By shifting away from reliance on naturally occurring compounds, the company can design and produce millions of artificial natural products in a single week. This approach enables the discovery of novel chemical matter that goes beyond the limitations of evolutionary biology, specifically targeting previously undruggable disease areas.

The company serves pharmaceutical, biotechnology, and agribusiness partners by generating custom-designed molecule libraries and focused biopharmaceutical candidates. By integrating cutting-edge science from institutions such as ETH Zurich and the Max Planck Institute, Myria aims to accelerate the discovery and optimization of therapeutic candidates. The platform’s ability to generate high-throughput data and access vast, previously uncharted chemical space supports the development of targeted, high-precision biopharmaceuticals for unmet medical needs. Following a successful pre-seed funding round in 2024, the company is advancing its internal pipeline and collaborating with industry partners.